---
document_datetime: 2026-02-18 11:30:33
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zemcelpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zemcelpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3669856
conversion_datetime: 2026-02-21 13:00:49.420529
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Zemcelpro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 17/02/2026                          |                                             | Labelling and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000325403                      | Update of the labelling to add information to be included on the SafePak label covering both cell components as well as information to be included on the infusion bag (pouch) label for both, dorocubicel expanded CD34+ cells and unexpanded CD34- cells. Additionally, the MAH updated the package leaflet to reflect the correct name of the marketing authorisation holder and manufacturer in section \"6. Contents of the pack and other information\".                                         | PL                     |                                                                                                                                                                  |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000316958 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update the SmPC by correcting the Leukopenia percentage in Section 4.8 and the data for Acute Lymphoid Leukaemia and Myelodysplastic Syndrome in Section 5.1. In addition, the MAH took the opportunity to implement editorial changes to (1) update the MAHs phone number in the Annexes, (2) correct a translation error in the FR SmPC, and (3) correct a typographical error in the FI SmPC. | SmPC, Labelling and PL | To update the SmPC by correcting the Leukopenia percentage in Section 4.8 and the data for Acute Lymphoid Leukaemia and Myelodysplastic Syndrome in Section 5.1. |